KDR and cystitis: In addition, there is an evidence of higher PDGFR-ß expression in bladder UC samples comparing with normal bladder and cystitis samples66, suggesting a potential clinical use of toceranib phosphate (VEGFR-2 and PDGFR-ß inhibitor).